|Description||BMS-582949 hydrochloride is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 of 13 nM. It displays >2000-fold selectivity for p38α over a diverse panel of 57 kinases including serine kinases, nonreceptor tyrosine kinases, receptor tyrosine kinases, and the p38γ and δ isoforms. It is a weak inhibitor of CYP3A4, with an IC50 value ranging from 18 to 40 μM based in multiple tests. It does not significantly inhibit cytochrome P450 isozymes 1A2, 2C9, 2C19, and 2D6 in vitro. It exhibited oral bioavailability values of 90% and 60% in mice and rats, respectively. It is currently under Phase II clinical trials for the treatment of inflammatory diseases.|
|Synonyms||BMS 582949 hydrochloride;4-((5-((Cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propylpyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide|
|Solubility||DMSO: ＞ 35 mg/mL|
|Application||BMS-582949 hydrochloride is used for the treatment of inflammatory diseases.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||BMS-582949 hydrochloride is currently under Phase II clinical trials.|
CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...
PH-797804 is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase. PH-797804 exhibited exceptionally high specificity against MAP kinases ...
SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated...
SB 203580 hydrochloride
SB 203580 hydrochloride is a water-soluble form of the potent MAP kinase inhibitor SB 203580. It is a selective inhibitor of p38 mitogen-activated protein kinas...
RPR-200765A Mesylayte, a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM), could exhibit a profile of disease modifying activity in rheumatoid ar...
An inhibitor of p38 kinase
SD-06 is an inhibitor of p38α (IC50=170 nM).
LY2228820 dimesylate is a highly selective small molecule inhibitor of p38α(IC50=7 nM) and p38β mitogen-activated protein kinases (MAPKs).
SKF-86002 is a p38 MAP kinase inhibitor, the IC50 is 0.1 - 1 μM. It potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes, the IC50 is1 μM....
Doramapimod (BIRB 796) is a member of the N-pyrazole-N'-naphthly urea class of p38MAPK inhibitors, which binds to the kinase with both slow association and diss...
SB 202190 is a potent inhibitor of p38 MAPK. It inhibits the p38α and β isoforms with IC50 of 50 nM/100 nM at SAPK2a/p38 and SAPK2b/p38β2.
BMS582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 value of 13nM, which plays a crucial role in regulating ...
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that ...
SB202190, also named FHPI, under the IUPAC name 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one, is a pyridinyl imid...
AMG-548 is a selective p38α inhibitor with Ki value of 0.5nM. It displays >1000-fold selectivity against 36 other kinases, and it can inhibit whole blood LPS-st...
TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK...
FR-167653, a pyrazolotriazin derivative, has been found to be a cytokine inhibitor as well as P38 mitogen-activated protein kinase inhibitor and was once studi...
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the developm...
TA-02 is a p38 MAPK inhibitor ( IC50 = 20 nM ).
Skepinone-L is a selective p38α-MAPK inhibitor with IC50 of 5 nM.